Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

BioXcel Therapeutics (BTAI) Equity Ratio (2022 - 2025)

BioXcel Therapeutics (BTAI) has 4 years of Equity Ratio data on record, last reported at 1.99 in Q3 2025.

  • For Q3 2025, Equity Ratio fell 13.34% year-over-year to 1.99; the TTM value through Sep 2025 reached 1.99, down 13.34%, while the annual FY2024 figure was 2.43, 216.73% down from the prior year.
  • Equity Ratio reached 1.99 in Q3 2025 per BTAI's latest filing, up from 4.17 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.92 in Q1 2022 and bottomed at 4.17 in Q2 2025.
  • Average Equity Ratio over 4 years is 0.87, with a median of 0.77 recorded in 2023.
  • Peak YoY movement for Equity Ratio: crashed 2812.81% in 2024, then dropped 13.34% in 2025.
  • A 4-year view of Equity Ratio shows it stood at 0.37 in 2022, then crashed by 305.57% to 0.77 in 2023, then plummeted by 216.73% to 2.43 in 2024, then rose by 18.25% to 1.99 in 2025.
  • Per Business Quant database, its latest 3 readings for Equity Ratio were 1.99 in Q3 2025, 4.17 in Q2 2025, and 2.34 in Q1 2025.